Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Tumor, Adult × Jupiter × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor, Adult 1

Interventions

pembrolizumab 3 toripalimab 1 spartalizumab 1 sotorasib 1 pazopanib 1 palbociclib 1 abemaciclib 1 Trastuzumab 1 Therapeutics 1 Jupiter 1 Interleukin-2 1 Immune Checkpoint Inhibitors 1 Fulvestrant 1 EBI-005 1 Cetuximab 1 Catalytic Domain 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed

40 enrolled 16 charts

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡